Unknown

Dataset Information

0

Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.


ABSTRACT: BACKGROUND:We found previously that bovine pulmonary Surfacten® used in newborns with acute respiratory distress syndrome is a safe and efficacious antigen vehicle for intranasal vaccination. OBJECTIVES:The objective of this study was to industrially produce a synthetic adjuvant mimicking Surfacten® for clinical use without risk of bovine spongiform encephalopathy. METHODS:We selected three Surfacten lipids and surfactant protein (SP)-C as essential constituents for adjuvanticity. For replacement of the hydrophobic SP-C, we synthesized SP-related peptides and analyzed their adjuvanticity. We evaluated lyophilization to replace sonication for the binding of influenza virus hemagglutinin (HA) to the synthetic adjuvant. We also added a carboxy vinyl polymer (CVP) to the synthetic adjuvant and named the mixture as SF-10 adjuvant. HA combined with SF-10 was administered intranasally to mice, and induction of nasal-wash HA-specific secretory IgA (s-IgA) and serum IgG with Th1-/Th2-type cytokine responses in nasal cavity and virus challenge test were assessed. RESULTS AND CONCLUSIONS:Intranasal immunization with HA-SF-10 induced significantly higher levels of anti-HA-specific nasal-wash s-IgA and serum IgG than those induced by HA-poly(I:C), a reported potent mucosal vaccine, and provided highly efficient protection against lethal doses of virus challenge in mice. Anti-HA-specific serum IgG levels induced by HA-SF-10 were almost equivalent to those induced by subcutaneous immunization of HA twice. Intranasal administration of HA-SF-10 induced balanced anti-HA-specific IgG1 and IgG2a in sera and IFN-?- and IL-4-producing lymphocytes in nasal cavity without any induction of anti-HA IgE. The results suggest that HA-SF-10 is a promising nasal influenza vaccine and that SF-10 can be supplied in large quantities commercially.

SUBMITTER: Kimoto T 

PROVIDER: S-EPMC3933764 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.

Kimoto Takashi T   Mizuno Dai D   Takei Tsunetomo T   Kunimi Takuya T   Ono Shinji S   Sakai Satoko S   Kido Hiroshi H  

Influenza and other respiratory viruses 20130526 6


<h4>Background</h4>We found previously that bovine pulmonary Surfacten® used in newborns with acute respiratory distress syndrome is a safe and efficacious antigen vehicle for intranasal vaccination.<h4>Objectives</h4>The objective of this study was to industrially produce a synthetic adjuvant mimicking Surfacten® for clinical use without risk of bovine spongiform encephalopathy.<h4>Methods</h4>We selected three Surfacten lipids and surfactant protein (SP)-C as essential constituents for adjuvan  ...[more]

Similar Datasets

| S-EPMC4637982 | biostudies-literature
| S-EPMC7403488 | biostudies-literature
| S-EPMC7540734 | biostudies-literature
| S-EPMC5595963 | biostudies-literature
| S-EPMC4979151 | biostudies-literature
| S-EPMC3273652 | biostudies-literature
| S-EPMC4896793 | biostudies-literature
| S-EPMC3496939 | biostudies-literature
| S-EPMC7115557 | biostudies-literature
| S-EPMC10675063 | biostudies-literature